Veru Inc (VERU) Director Buys $10,206.00 in Stock
Veru Inc (NASDAQ:VERU) Director Jesus Socorro acquired 5,400 shares of the firm’s stock in a transaction on Thursday, September 6th. The stock was purchased at an average cost of $1.89 per share, with a total value of $10,206.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
NASDAQ VERU traded up $0.06 during trading on Friday, hitting $1.91. The stock had a trading volume of 7,425 shares, compared to its average volume of 92,847. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.01 and a quick ratio of 0.80. The company has a market cap of $107.25 million, a P/E ratio of -7.80 and a beta of 0.69. Veru Inc has a one year low of $0.90 and a one year high of $3.00.
Veru (NASDAQ:VERU) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.07). Veru had a negative return on equity of 38.09% and a negative net margin of 130.26%. The firm had revenue of $5.50 million during the quarter, compared to the consensus estimate of $5.20 million. equities research analysts expect that Veru Inc will post -0.33 EPS for the current year.
Several brokerages have issued reports on VERU. HC Wainwright set a $5.00 price objective on shares of Veru and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Maxim Group reissued a “buy” rating and issued a $10.00 price objective on shares of Veru in a research note on Monday, August 27th. Zacks Investment Research downgraded shares of Veru from a “hold” rating to a “sell” rating in a research note on Tuesday, August 21st. ValuEngine raised shares of Veru from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Finally, Dawson James reissued a “buy” rating on shares of Veru in a research note on Monday, June 25th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $5.83.
Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Featured Story: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.